NFSG
MCRB icon

Newbridge Financial Services Group’s Seres Therapeutics MCRB Stock Holding History

Newbridge Financial Services Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$131 – 1267
2023
Q3 		$131 Hold
3
– – ﹤0.01% 1245
2023
Q2 		$263 Hold
3
– – ﹤0.01% 1282
2023
Q1 		$312 Hold
3
– – ﹤0.01% 1339
2022
Q4 		$308 Hold
3
– – ﹤0.01% 1376
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1437
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1453
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1506
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1488
2021
Q3 		$1K Hold
3
– – ﹤0.01% 1278
2021
Q2 		$1K Hold
3
– – ﹤0.01% 1368
2021
Q1 		$1K Buy
+3
New +$1.38K ﹤0.01% 1291

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newbridge Financial Services Group's MCRB Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 3 shares — an estimated $131 sold.

Newbridge Financial Services Group first reported a position in MCRB in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q3 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 3 Seres Therapeutics shares in Q4 2023, an estimated $131.
  • Newbridge Financial Services Group first reported a position in Seres Therapeutics in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Seres Therapeutics position peaked at $1K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.